Literature DB >> 22139535

Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.

Yoon Ki Joung1, Sejin Son, Ji Young Jang, Myung Hee Kwon, Ki Dong Park.   

Abstract

PURPOSE: Cytoplasmic delivery of a monoclonal antibody (mAb) with nucleic acid-hydrolyzing activity (3D8 scFv) using poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) was investigated for persistent anti-viral effect.
METHODS: 3D8 scFv-loaded PLGA (3D8-PLGA) NPs were prepared via a double emulsion method that was previously optimized. Flow cytometry and confocal microscopy was carried out to confirm the cellular uptake and cytoplasmic localization. immunochemical and fluorescence resonance energy transfer (FRET) assays tested the cytoplasmic release and hydrolyzing effect of 3D8 scFv, respectively. Anti-viral activity test was performed using MTT assay with vesicular stomatitis virus (VSV)-infected HeLa cells.
RESULTS: 3D8-PLGA NPs were much more effectively taken into cells in dose- and time-dependent manner and localized in the cytosolic region, compared to free 3D8 scFv. 3D8 scFv was released and hydrolyzed RNAs in the cytoplasm, exhibiting the maxima at a period of time (12-24 h). Anti-viral activity test revealed that 3D8-PLGA NP has dose- and time-dependent anti-viral effect and the maximum effect at the dose of 2 mg/ml and the incubation of 3 days.
CONCLUSIONS: Cytoplasmic delivery of 3D8 scFv via PLGA NPs could enhance the viability of infected cells in sustained manner due to preserved activity, much improved cellular uptake and sustained release.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139535     DOI: 10.1007/s11095-011-0633-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

Review 1.  Anti-DNA antibodies: aspects of structure and pathogenicity.

Authors:  Y J Jang; B D Stollar
Journal:  Cell Mol Life Sci       Date:  2003-02       Impact factor: 9.261

2.  New advances in microsphere-based single-dose vaccines.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

Review 3.  Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy.

Authors:  W C Bogard; R T Dean; Y Deo; R Fuchs; J A Mattis; A A McLean; H J Berger
Journal:  Semin Nucl Med       Date:  1989-07       Impact factor: 4.446

4.  Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles.

Authors:  Jayanth Panyam; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

Review 5.  Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery.

Authors:  Mei Lin Tan; P F M Choong; C R Dass
Journal:  Peptides       Date:  2009-10-09       Impact factor: 3.750

6.  An RNA-hydrolyzing recombinant antibody exhibits an antiviral activity against classical swine fever virus.

Authors:  Hye-Ryeong Jun; Chuong D Pham; Seong-In Lim; Suk-Chan Lee; Yong-Sung Kim; Sun Park; Myung-Hee Kwon
Journal:  Biochem Biophys Res Commun       Date:  2010-04-09       Impact factor: 3.575

Review 7.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.

Authors:  Wenlei Jiang; Rajesh K Gupta; Mangesh C Deshpande; Steven P Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2005-01-10       Impact factor: 15.470

8.  Monoclonal anti-DNA antibodies: structure, specificity, and biology.

Authors:  T N Marion; M R Krishnan; D D Desai; N T Jou; D M Tillman
Journal:  Methods       Date:  1997-01       Impact factor: 3.608

Review 9.  Polysaccharides-based nanoparticles as drug delivery systems.

Authors:  Zonghua Liu; Yanpeng Jiao; Yifei Wang; Changren Zhou; Ziyong Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-09-17       Impact factor: 15.470

10.  Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres.

Authors:  H Suh; B Jeong; R Rathi; S W Kim
Journal:  J Biomed Mater Res       Date:  1998-11
View more
  1 in total

1.  Antiviral nanoagents: More attention and effort needed?

Authors:  Yongjiu Chen; Juan Ma; Ming Xu; Sijin Liu
Journal:  Nano Today       Date:  2020-09-18       Impact factor: 18.962

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.